BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Thrombotic Microangiopathy readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Thrombotic Microangio
 pathy\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07707687-886@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20280710
DTEND;VALUE=DATE:20280711
SUMMARY:Soliris (Eculizumab): Phase 2 readout est. (NCT07707687)
DESCRIPTION:Soliris (Eculizumab)\, phase 2\, Thrombotic Microangiopathy.\nS
 tudy: Safety and Efficacy of Eculizumab in High-risk TA-TMA\nEstimated pri
 mary completion: 10 July 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/eculizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07707687
URL:https://assetmemo.bio/drug/eculizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
